The shareholders in Pandox Aktiebolag (publ) are hereby summoned to an annual shareholders’ meeting to be held on 3 May 2016 at 14.00 CEST at Hilton Stockholm Slussen, Guldgränd 8, 104 65 Stockholm.
Shareholders who wish to participate in the shareholders’ meeting must:
firstly be included in the shareholders’ register maintained by Euroclear Sweden AB as of 27 April 2016; and
secondly notify the company of their participation in the shareholders’ meeting no later than 27 April 2016. The notification shall be in writing to Pandox Aktiebolag, Årsstämma 2016, c/o Euroclear Sweden AB, Box 191, 101 23 Stockholm or via telephone +46 (0)8 402 91 53. The notification shall state the name, personal/corporate identity number, shareholding, address and daytime telephone number, and information about any assistants and, where applicable, representatives. When applicable, complete authorisation documents, such as powers of attorney for representatives, registration certificates or corresponding documents, shall be appended to the notification.
Nominee registered shares
Shareholders whose shares have been registered in the name of a bank or securities institute must temporarily re-register their shares in their own names with Euroclear Sweden AB in order to be entitled to participate in the shareholders’ meeting. Shareholders wishing such re-registration must inform their nominee of this well before 27 April 2016, when such re-registration must have been completed.
Shareholders represented by proxy shall issue a dated and signed power of attorney for the proxy. If the power of attorney is issued on behalf of a legal entity, a certified copy of a registration certificate or a corresponding document for the legal entity shall be appended. The power of attorney is valid for a maximum of one year after the issuance or for the duration indicated in the power of attorney, whichever is longer, but not for more than five years after issuance. The registration certificate, where applicable, may not be older than one year. The power of attorney in original and, where applicable, the registration certificate should be submitted to the company by mail at the address set forth above well in advance of the shareholders’ meeting. The form to use for a power of attorney can be found on www.pandox.se.
Shareholders’ right to request information
Shareholders are reminded of their right to request information in accordance with Chapter 7 Section 32 of the Swedish Companies Act (Sw. aktiebolagslagen).
Number of shares and votes
There are a total of 75,000,000 class A shares, with 225,000,000 votes, and 75,000,000 class B shares, with 75,000,000 votes, in the company as of the date of this notice.
1. Opening of the meeting;
2. Election of a chairman at the meeting;
3. Preparation and approval of the voting list;
4. Approval of the agenda;
5. Election of two persons who shall approve the minutes of the meeting;
6. Determination as to whether the meeting has been duly convened;
7. Submission of the annual report and the auditors’ report and the consolidated financial statements and the auditors’ report for the group;
8. Resolutions regarding:
a. adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet;
b. allocation of the company’s profits or losses in accordance with the adopted balance sheet;
c. discharge of the members of the board of directors and the CEO from liability;
9. Determination of the number of members of the board of directors to be elected by the shareholders’ meeting and the number of auditors and, where applicable, deputy auditors;
10. Determination of fees for members of the board of directors and auditors;
11. Election of the members of the board of directors;
12. Election of auditors and, where applicable, deputy auditors;
13. The nomination committee’s proposal for principles for appointment of a nomination committee for the annual shareholders’ meeting 2017;
14. The board of directors’ proposal for guidelines for remuneration for members of management;
15. The board of directors’ proposal on authorisation for the board of directors to resolve on new share issues;
16. Closing of the meeting.
The nomination committee’s proposals
Proposal regarding the chairman of the annual shareholders’ meeting, the number of members of the board of directors, the number of auditors and deputy auditors, fees to the board of directors and auditors, and election of members of the board of directors, as well as election of auditors and deputy auditors (items 2 and 9-12)
The nomination committee, consisting of Anders Ryssdal (representing Eiendomsspar Sverige AB) Christian Ringnes (chairman of the board of directors), Lars-Åke Bokenberger (representing AMF – Försäkring och Fonder), Marianne Flink (representing Swedbank Robur fonder) and Johannes Wingborg (representing Länsförsäkringar Fondförvaltning AB), has submitted the following proposals:
- Christian Ringnes is proposed to chair the annual shareholders’ meeting (item 2).
- The number of members of the board of directors shall be seven, with no deputy members (item 9).
- The following fees to the board of directors are proposed (fees for 2015 in brackets):
o A fee to the chairman of the board of directors of SEK 600,000 (600,000) and a fee of SEK 400,000 (400,000) to each of the other board members elected by the shareholders’ meeting.
o A fee of SEK 50,000 (50,000) to each of the two members, the chairman included, of the remuneration committee.
o A fee to the chairman of the audit committee of SEK 130,000 (130,000) and a fee of SEK 70,000 (70,000) to each of the other two members of the audit committee.
The proposed board fees, including fees for work in committees, thereby amount to SEK 3,370,000 (3,450,000), a reduction of SEK 80,000 compared to the previous year. The reduction is explained by the establishment of an audit committee with three members, which fulfills the duties that the board previously fulfilled in its entirety. The level of the fees is motivated by the complexity of Pandox’ business and the high level of activity of the board. Board fees may be invoiced through a company in a way that is cost neutral for Pandox. It is proposed that auditor fees shall be paid in accordance with approved invoice (item 10).
- Christian Ringnes, Leiv Askvig, Ann-Sofi Danielsson, Bengt Kjell, Olaf Gauslå, Helene Sundt and Mats Wäppling are proposed for re-election as board members for the time until the end of the next annual shareholders’ meeting. Christian Ringnes is proposed for re-election as chairman of the board of directors (item 11).
- Authorised public accountant Per Gustafsson (KPMG AB) and authorised public accountant Willard Möller (Mazars SET AB) are proposed for re-election as auditors. Authorised public accountant Bengt Ekenberg (Mazars SET AB) is proposed for election and Ulf Christer Sundborg (KPMG AB) is proposed for re-election as deputy auditors (item 12).
The nomination committee’s proposal for principles for appointment of a nomination committee for the annual shareholders’ meeting 2017 (item 13)
It is proposed that the nomination committee for the annual shareholders’ meeting 2017 is appointed in accordance with the following:
Ahead of annual shareholders’ meeting 2017, the nomination committee shall be composed of representatives of the four largest shareholders listed in the shareholders’ register maintained by Euroclear Sweden as of 31 July 2016 together with the chairman of the board of directors, who will also convene the first meeting of the nomination committee. If a shareholder, who is entitled to appoint a representative to the nomination committee, abstains from appointing a representative, the right to appoint a representative shall pass to the largest shareholder who was previously not entitled to appoint a representative to the nomination committee. The member of the nomination committee representing the largest shareholder shall be appointed chairman of the nomination committee.
If earlier than two months prior to the annual shareholders’ meeting 2017, one or more of the shareholders having appointed representatives to the nomination committee no longer are among the four largest shareholders, representatives appointed by these shareholders shall offer to resign and the shareholders who then are among the four largest shareholders may appoint their representatives.
Should a member resign from the nomination committee before its work is completed and the nomination committee considers it necessary to replace him or her, such substitute member is to represent the same shareholder or, if the shareholder is no longer one of the largest shareholders, the largest shareholder in turn.
Changes to the composition of the nomination committee must be announced immediately. The composition of the nomination committee shall be announced no later than six months before the annual shareholders’ meeting.
Remuneration shall not to be paid to the members of the nomination committee. The Company is, however, to pay any necessary expenses that the nomination committee may incur in its work.
The term of office for the nomination committee ends when the composition of the following nomination committee has been announced.
The board of directors’ proposals
Allocation of the company’s profits or losses in accordance with the adopted balance sheet (item 9b)
The funds at the meeting’s disposal consists of the profit of the year, SEK 570,689,458 and the company’s accumulated results, SEK 1,885,181,253, in total SEK 2,455,870,711.
The board proposes that the funds at the meeting’s disposal, SEK 2,455,870,711, shall be allocated as dividends to the shareholders of SEK 3.80 per share, in total SEK 570,000,000, and that the remaining unrestricted equity, SEK 1,885,870,711, is carried forward. Friday 6 May 2016 is suggested as record day for dividends. If the annual shareholders’ meeting adopts a resolution in accordance with the proposal, the dividend is estimated to be paid through Euroclear Sweden on Wednesday 11 May 2016.
The board of directors’ proposal for guidelines for remuneration for members of management (item 14)
The board of directors proposes that the annual shareholders’ meeting resolves to adopt the following guidelines for the remuneration of the members of management.
Remuneration in Pandox should be competitive in comparison to that of similar companies in order to attract, motivate and retain key employees. The purpose is to provide incentives for members of management to execute strategic plans and to deliver good results as well as to align the interests of members of management with the interests of the shareholders.
Total remuneration shall consist of base salary, short-term incentive programs as well as long-term share price based incentive programs (“LTI-programs”), in addition to pension and other customary benefits.
- Base salary depends on the complexity of work and the individual's performance and competence. The salary shall be on market terms and competitive. Salary levels are to be reviewed annually.
- Short-term incentive programs shall be based on company-wide and individual targets. For members of management in Pandox, remuneration from the short-term incentive programs shall amount to not more than four months’ salary.
- Vesting periods for LTI-programs shall be at least five years. LTI-programs shall be share-based, share price-based, or based on share -related instruments and shall be cash settled. LTI-programs shall provide long term incentives related to Pandox’ development.
- Agreements concerning pensions for members of management shall, wherever possible, be based on fixed premiums and be in accordance with the levels, practice and collective bargaining agreements applicable in the country where the relevant member of management is employed.
- Other benefits may consist of health insurance and other customary benefits. Other benefits shall not be a significant part of the total remuneration.
- In the event of termination of employment by Pandox, the notice period of termination shall be not more than 12 months.
The board of directors may deviate from these guidelines under special circumstances that motivate such deviation.
The board of directors’ proposal on authorisation for the board of directors to resolve on new share issues (item 15)
The board of directors proposes that the annual shareholders’ meeting authorises the board to resolve – at one or several occasions and for the time period until the next annual shareholders’ meeting – to increase the company’s share capital by new share issues, to the extent that it corresponds to a dilution of not more than 10 percent of the number of shares outstanding at the time of the notice of the annual shareholders’ meeting, after full exercise of the hereby proposed authorisation. New share issues may be made with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions. Pursuant to Chapter 16 of the Swedish Companies Act, the board of directors may not by virtue of this authorisation resolve on issues to board members in group companies, employees, etc. The purpose of the authorisation is to increase the financial flexibility of the company and the acting scope of the board. Should the board of directors resolve on an issue with deviation from the shareholder’s preferential rights, the reason shall be to finance an acquisition of property companies, properties or hotel related businesses. Upon such deviation from the shareholders’ preferential rights, the new issue shall be made at market terms and conditions.
A resolution in accordance with the board’s proposal under item 15 shall only be valid where supported by not less than two-thirds (2/3) of both the votes cast and the shares represented at the meeting.
The nomination committee’s proposals under items 2, 9-13, and the board of directors’ proposal under items 14-15 above will no later than 12 April 2016 be available at the company’s office, Vasagatan 11, 111 20 Stockholm and at the company’s webpage, www.pandox.se, and be sent to shareholders that so request and inform the company of their postal address.
Stockholm, March 2016
Pandox Aktiebolag (publ)
The board of directors
FOR MORE INFORMATION, PLEASE CONTACT:
Christian Ringnes, Chairman of the Board, +47 22 33 05 50
Pandox AB (publ) is required to publish this information under the Swedish Securities Market Act and/or Financial Instruments Trading Act. The information was submitted for publication on 30 March 2016 at 08:10 CEST.
Pandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio currently comprises 121 hotels with more than 25,000 hotel rooms in eight countries. Pandox’s business is organised into Property management, which comprises hotel properties leased on a long-term basis to market leading regional hotel operators and leading international hotel operators, and Operator activities, which comprises hotel operations executed by Pandox in its owner-occupied hotel properties. Pandox was founded in 1995 and the company’s B shares are, as of 18 June 2015, listed on Nasdaq Stockholm. www.pandox.se